Fujifilm Pharmaceuticals U.S.A.

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Fujifilm Pharmaceuticals U.S.A. sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Fujifilm Pharmaceuticals U.S.A.: 8 sponsored US clinical trials, none currently recruiting.

Fujifilm Pharmaceuticals U.S.A. sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumors, with 2 trials.

Upper-quartile sponsor footprint

Fujifilm Pharmaceuticals U.S.A. sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

NCT05318573
ACTIVE NOT RECRUITING Phase 1

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma

NCT04047251
ACTIVE NOT RECRUITING Phase 1

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer

NCT03440450
COMPLETED Phase 2

Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19

NCT04358549
COMPLETED Phase 1

Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03194685
COMPLETED Phase 1

A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer

NCT02454010
COMPLETED Phase 1

Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas

NCT02661542
COMPLETED Phase 1

Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

NCT02193958

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 2

Therapeutic Areas

Advanced Solid Tumors 2
Advanced Urothelial Carcinoma 1
Advanced Non-Small-Cell Lung Cancer 1
Merkel Cell Carcinoma 1
Biliary Tract Cancer 1
Solid Tumor 1

How the Fujifilm Pharmaceuticals U.S.A. early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Advanced Solid Tumors (2 trials), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Fujifilm Pharmaceuticals U.S.A.: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Fujifilm Pharmaceuticals U.S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Fujifilm Pharmaceuticals U.S.A.AB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Fujifilm Pharmaceuticals U.S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Fujifilm Pharmaceuticals U.S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Fujifilm Pharmaceuticals U.S.A. page

8 registered trials is a research-attention snapshot, not an endorsement of Fujifilm Pharmaceuticals U.S.A. or any single study.

  • None of Fujifilm Pharmaceuticals U.S.A.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Advanced Solid Tumors is the condition Fujifilm Pharmaceuticals U.S.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Fujifilm Pharmaceuticals U.S.A. pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.